When multiple myeloma relapses
RESPOND with a treatment with a tolerable safety profile
Kd adverse events
In the ENDEAVOR trial there was a longer treatment duration
in the Kd arm vs the Rd arm (40 vs 27 weeks, respectively).1
AE-related discontinuation rates* were similar between Kd and Vd arms.1
Refer to Summary of Product Characteristics and Prescribing Information for comprehensive safety information
Frequency of AEs may vary between studies. Refer to SmPC for selected AEs reported in clinical studies.2 *In the intention-to-treat population: Kd (n=464) and Vd (n=465).
Please read the SmPC for full comprehensive safety information
- Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
- Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.